Foghorn Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $7,557 | $5,952 | $2,856 | $7,808 |
Gross Profit | 6,657 | 5,952 | 2,856 | 7,808 |
EBITDA | -17,036 | -22,086 | -23,244 | -23,119 |
EBIT | -17,936 | -22,913 | -24,005 | -23,852 |
Net Income | -17,936 | -18,834 | -19,503 | -19,122 |
Net Change In Cash | 7,557 | 5,952 | 2,856 | 7,808 |
Free Cash Flow | -21,022 | -23,996 | -24,998 | -21,314 |
Cash | 73,822 | 61,026 | 55,454 | 57,678 |
Basic Shares | 62,978 | 62,848 | 62,602 | 62,602 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $22,602 | $34,155 | $19,228 | $1,319 |
Gross Profit | 22,602 | -75,534 | 19,208 | -6,196 |
EBITDA | -97,165 | -104,455 | -113,816 | -96,187 |
EBIT | -100,285 | -107,906 | -117,137 | -103,702 |
Net Income | -86,620 | -98,426 | -108,873 | -103,226 |
Net Change In Cash | 22,602 | 34,155 | 19,228 | 1,319 |
Cost of Revenue | -48,947 | 8,341 | ||
Free Cash Flow | -101,312 | -119,330 | 192,402 | -53,563 |
Cash | 55,454 | 80,336 | 345,798 | 101,136 |
Basic Shares | 54,899 | 41,974 | 41,591 | 37,171 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.28 |
2025-03-31 | -$0.30 |
2024-12-31 | -$0.30 |
